Vaxcyte (PCVX) Stock Price, News & Analysis

Company Overview

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company’s lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes.

Vaxcyte’s pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes. The company also applies its cell-free protein synthesis and conjugation technologies to support the development of vaccines for additional bacterial pathogens.

Founded in 2016 as SutroVax and later renamed Vaxcyte, the company is headquartered in San Carlos, California. Its programs are developed through clinical research and collaborations involving sites and participants in the United States and other regions. Grant Pickering, Ph.D., serves as Vaxcyte’s president and chief executive officer.

Key Stats

• Today's Range: $57.62 to $60.54
• 50-Day Range: $52.98 to $63.30
• 52-Week Range: $31.51 to $65.00
• Volume: 1.12 million shs
• Average Volume: 1.38 million shs
• Market Capitalization: $8.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $98.00
• Consensus Rating: Moderate Buy

Vaxcyte Stock Analysis - MarketRank™

Vaxcyte scored higher than 44% of companies evaluated by MarketBeat, and ranked 597th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vaxcyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vaxcyte has a consensus price target of $98.00, representing about 65.0% upside from its current price of $59.39.

Amount of Analyst Coverage

Vaxcyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vaxcyte are expected to grow in the coming year, from ($7.60) to ($6.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxcyte is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxcyte is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxcyte has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.44% of the float of Vaxcyte has been sold short.

Short Interest Ratio / Days to Cover

Vaxcyte has a short interest ratio ("days to cover") of 15.86, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxcyte has recently increased by 1.49%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxcyte does not currently pay a dividend.

Dividend Growth

Vaxcyte does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.30

News Sentiment

Vaxcyte has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Vaxcyte this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,021,389.00 in company stock.

Percentage Held by Insiders

3.30% of the stock of Vaxcyte is held by insiders.

Percentage Held by Institutions

96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PCVX
• CIK: 1649094
• Web: www.vaxcyte.com
• Phone: 650-837-0111
• Fax: N/A
• Employees: 507
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Vaxcyte: $98.00
• High Price Target: $116.00
• Low Price Target: $77.00
• Potential Upside/Downside: +66.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$766.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.56%
• Return on Assets: -33.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.72
• Quick Ratio: 5.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.51 per share
• Price / Book: 2.87

Miscellaneous

• Outstanding Shares: 148,805,000
• Free Float: 143,894,000
• Market Cap: $8.77 billion
• Optionable: Optionable
• Beta: 1.22